UPEI researchers collaborating with partners to develop novel drug therapy to potentially slow ALS

Two researchers from UPEI are collaborating with colleagues at the Research Institute of the McGill University Health Centre (The Institute) and Neurodyn Life Sciences Inc., a PEI-based biotechnology company, on a project to develop a novel therapy to slow, or potentially functionally stabilize, the progression of amyotrophic lateral sclerosis (ALS).

Subscribe to